NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has announced the appointment of Christopher Cleary as an independent member of its Board of Directors, effective January 30, 2025. A medical device industry veteran, Cleary brings over 30 years of expertise in corporate development, mergers, acquisitions, and R&D collaborations that align closely with Orchestra BioMed’s partnership-driven business model.
Previously, Cleary served as Senior Vice President of Corporate Development at Medtronic plc, where he played a pivotal role in establishing the strategic collaboration between Medtronic and Orchestra BioMed for atrioventricular interval modulation (AVIM) therapy, aimed at addressing hypertension in patients with elevated cardiovascular risk. Over the course of his career, Cleary has been instrumental in closing over 200 transactions across various markets, facilitating Medtronic’s growth through acquisitions, strategic investments, and operational expansions.
“We’re thrilled to welcome Chris as an independent member of the Orchestra BioMed Board of Directors, a role in which we expect he will provide invaluable guidance to help us more effectively execute our novel, partnership-enabled business model,” said David Hochman, Chairman, CEO, and Founder of Orchestra BioMed. “With his extensive experience in global strategy, dealmaking, investing, and partnering, Chris brings knowledge and experience that is directly relevant to our strategy, technologies, and pathways to success.”
Cleary expressed his enthusiasm for the new role, commenting, “I am excited to join the Orchestra BioMed Board of Directors and contribute to the Company’s bold mission of accelerating medical device innovation in cardiovascular disease through strategic partnerships. Orchestra BioMed’s collaboration with Medtronic for AVIM therapy, which I had the opportunity to help shape, is a great example of this business at work.”
Leadership Transition
The company also announced the transition of Eric A. Rose, M.D., from Board Member to Board Member Emeritus and Strategic Advisor. A long-standing member of Orchestra BioMed’s leadership, Rose will remain actively engaged in an advisory capacity, sharing his extensive expertise to support the company’s initiatives and long-term growth.
With Cleary’s proven track record in corporate strategy and Rose’s continued advisory role, Orchestra BioMed is well-positioned to advance its innovative device-based therapies, including AVIM therapy and Virtue SAB. These leadership changes are expected to further strengthen the company’s ability to deliver impactful solutions in cardiovascular medicine.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.